Solid tumours are often heterogeneous, they contain a diverse range of cancer cells with varying characteristics ...

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

For more information, please refer to the full article in JAMA Oncology.

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...

The global cell therapy manufacturing market is poised for remarkable growth, with market size expected to reach USD 15,634.67 million by 2033, according to recent market projections. In 2023, the ...

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

For many doctors and researchers, immunotherapy that uses someone’s own immune system to target and attack cancer cells is the next and best frontier of cancer treatment.

Civilization 7 is adding a lot of new features and mechanics to the series, and one system could be the most complex and ...

Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...